Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 1, 2012, Pages 49-58

  Zhou, Ping ^a   Hoffman, James ^b   Landau, Heather ^c   Hassoun, Hani ^c   Iyer, Lakshmanan ^d   Comenzo, Raymond L ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloidosis; BNP; Cyclin D1; Immunoglobulin light chains; Plasma cells

Indexed keywords

CYCLIN D1; M PROTEIN; PARAPROTEIN; SYNDECAN 1;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CELL CLONE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION PROFILING; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PLASMA CELL; PROTEIN QUALITY; PROTEIN SECRETION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CELLS, CULTURED; CLONE CELLS; CYCLIN D1; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA CELLS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84856853155     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.09.217     Document Type: Article

References (34)

1. G. Merlini, V. Bellotti Molecular mechanisms of amyloidosis N Engl J Med 349 2003 583 596 (Pubitemid 36951371)
2. G. Palladini, R.A. Kyle, D.R. Larson Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis Amyloid 12 2005 120 126 (Pubitemid 40978721)
3. P.L. Bergsagel, W.M. Kuehl, F. Zhan Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma Blood 106 2005 296 303 (Pubitemid 40967205)
4. D. Lesage, X. Troussard, B. Sola The enigmatic role of cyclin D1 in multiple myeloma Int J Cancer 115 2005 171 176 (Pubitemid 40586724)
5. M.A. Chapman, M.S. Lawrence, J.J. Keats Initial genome sequencing and analysis of multiple myeloma Nature 471 2011 467 472
6. R. Fonseca, P.L. Bergsagel, J. Drach International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 23 2009 2210 2221
7. S. Feyler, S.J. O'Connor, A.C. Rawstron IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14) Br J Haematol 140 2008 547 551 (Pubitemid 351230082)
8. P.L. Bergsagel, W.M. Kuehl Molecular pathogenesis and a consequent classification of multiple myeloma J Clin Oncol 23 2005 6333 6338 (Pubitemid 46218843)
9. M.A. Gertz, M.Q. Lacy, A. Dispenzieri Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy Blood 106 2005 2837 2840 (Pubitemid 41510761)
10. T. Bochtler, U. Hegenbart, F.W. Cremer Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood 111 2008 4700 4705
11. A.H. Bryce, R.P. Ketterling, M.A. Gertz Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica 94 2009 380 386
12. R.S. Abraham, K.V. Ballman, A. Dispenzieri Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis Blood 105 2005 794 803 (Pubitemid 40070767)
13. A.D. Cohen, P. Zhou, J. Chou Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone+/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial Br J Haematol 139 2007 224 233 (Pubitemid 47495869)
14. D. Lebovic, J. Hoffman, B.M. Levine Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone Br J Haematol 143 2008 369 373
15. M.A. Gertz, R. Comenzo, R.H. Falk Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004 Am J Hematol 79 2005 319 328 (Pubitemid 41098849)
16. P. Zhou, R.L. Comenzo, A.B. Olshen CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy Blood 111 2008 3403 3406
17. P. Zhou, J. Teruya-Feldstein, P. Lu Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan Blood 111 2008 549 557
18. J.W. Janssen, J.W. Vaandrager, T. Heuser Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32) Blood 95 2000 2691 2698 (Pubitemid 30210551)
19. D.G. Ginzinger Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream Exp Hematol 30 2002 503 512 (Pubitemid 34626648)
20. F. Hong, R. Breitling, C.W. McEntee RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis Bioinformatics 22 2006 2825 2827 (Pubitemid 44742407)
21. M. Dimopoulos, R. Kyle, J.P. Fermand Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 Blood 117 2011 4701 4705
22. B. Mueller, B.N. Lilley, H.L. Ploegh SEL1L, the homologue of yeast Hrd3p, is involved in protein dislocation from the mammalian ER J Cell Biol 175 2006 261 270 (Pubitemid 44631420)
23. R. Bernasconi, C. Galli, V. Calanca Stringent requirement for HRD1, SEL1L, and OS-9/XTP3-B for disposal of ERAD-LS substrates J Cell Biol 188 2010 223 235
24. S. Soverini, M. Cavo, C. Cellini Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation Blood 102 2003 1588 1594 (Pubitemid 37022546)
25. J. Buxbaum Aberrant immunoglobulin synthesis in light chain amyloidosis Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture J Clin Invest 78 1986 798 806 (Pubitemid 16024818)
26. G. Merlini, M.J. Stone Dangerous small B-cell clones Blood 108 2006 2520 2530
27. A. Dispenzieri, M.A. Gertz, R.A. Kyle Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 104 2004 1881 1887 (Pubitemid 39202301)
28. R. Sitia, G. Palladini, G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 92 2007 1302 1307 (Pubitemid 350144146)
29. D.E. Reece, V. Sanchorawala, U. Hegenbart Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study Blood 114 2009 1489 1497
30. D. Chauhan, G. Li, R. Shringarpure Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells Cancer Res 63 2003 6174 6177 (Pubitemid 37255160)
31. M. Deshmukh, K. Elderfield, A. Rahemtulla Immunophenotype of neoplastic plasma cells in AL amyloidosis J Clin Pathol 62 2009 724 730
32. A. Jaccard, P. Moreau, V. Leblond High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 2007 1083 1093 (Pubitemid 47443213)
33. E. Kostopoulou, D. Vageli, D. Kaisaridou Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR Breast 16 2007 615 624 (Pubitemid 350154451)
34. J. Hoffman, S. Jhanwar, R.L. Comenzo AL amyloidosis and progression to multiple myeloma with gain(1q) Br J Haematol 144 2009 963 964